Scientists from Nankai University Tianjin and Accendatech Technology Co. Ltd. have identified a majusculamide D derivative found to be useful for the treatment of cancer.

Haisco Pharmaceutical Group Co. Ltd. has divulged molecular glue degraders comprising cereblon (CRBN)-binding agents acting as proto-oncogene Vav (VAV1) degradation inducers. They are reported to be useful for the treatment of rheumatoid arthritis, multiple sclerosis and gastroenteritis.

Henan Normal University and Henan Zhiwei Biological Engineering Co. Ltd. have discovered macrocyclic compounds acting as neurotrophic tyrosine kinase receptors (TRK) and/or proto-oncogene tyrosine-protein kinase ROS (ROS1; MCF3) and/or hepatocyte growth factor receptor (HGFR; MET) and/or macrophage colony-stimulating factor 1 receptor (CSF1R; CD115; c-Fms) and/or ALK tyrosine kinase receptor inhibitors found to be potentially useful for the treatment of cancer and pain.

Researchers from Alicorn Pharmaceutical Co. Ltd. and Jiangsu Alicorn Pharmaceutical Co. Ltd. have disclosed crystalline salts of compounds acting as AP2-associated protein kinase 1 (AAK1) inhibitors that are potentially useful for the treatment of Alzheimer’s disease, bipolar disorder, Parkinson’s disease, diabetic peripheral neuropathy, postherpetic neuralgia (PHN) and schizophrenia.

Hangzhou Innogate Pharma Co. Ltd. has patented inhibitors of histone acetyltransferase KAT5 (Tip60) and/or KAT6A (MOZ; MYST-3) and/or KAT6B (MOZ2; MYST-4) and/or KAT7 (HBO-1; MYST-2) and/or KAT8 (hMOF; MYST-1) reported to be useful for the treatment of cancer.

Sunshine Lake Pharma Co. Ltd. has patented GTPase KRAS (G12C mutant) inhibitors found to be potentially useful for the treatment of cancer.

Insilico Medicine Inc. has identified sodium channel protein type 10 subunit α (SCN10A; Nav1.8) blockers that are potentially useful for the treatment of pain.

Researchers from Convalife Pharmaceuticals Co. Ltd. and Zhejiang Convalife Pharmaceutical Co. Ltd. have described dual CDK4/cyclin D1 and cyclin-dependent kinase 9 (CDK9) inhibitors reported to be useful for the treatment of cancer and inflammatory disorders.

Shanghai Pharmaceuticals Holding Co. Ltd. has reported interleukin-17A (IL-17A) inhibitors that are potentially useful for the treatment of psoriasis, rheumatoid arthritis, spondyloarthritis, hidradenitis suppurativa, psoriatic arthritis and uveitis.

Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. has disclosed heterocyclic compounds and their antibody-drug conjugates reported to be useful for the treatment of cancer.